We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In yet another setback for AstraZeneca, U.S. health officials raised concerns that the company included outdated information in its interim analysis of data from its U.S. phase 3 vaccine trial, prompting AZ to say it will release the results of its primary analysis by Thursday. Read More
Roche is stopping its phase 3 trial of tominersen, its investigational drug to treat Huntington’s disease, a rare neurodegenerative condition for which there is no known cure. Read More
Regeneron Pharmaceuticals’ and Roche’s antibody cocktail, REGEN-COV (casirivimab/imdevimab), reduced the risk of hospitalization or death by 70 percent in high-risk nonhospitalized COVID-19 patients in a late-stage trial, the companies have said. Read More
Roche’s blockbuster oncology drug Tecentriq (atezolizumab) met its primary endpoint of disease-free survival in its phase 3 lung cancer study evaluating the drug as an adjuvant therapy, according to an interim analysis. Read More
AstraZeneca’s (AZ) COVID-19 vaccine clocked in at 79 percent efficacy in preventing symptomatic infection and fully shielded against severe disease and hospitalization in the company’s phase 3 U.S. trial, opening the door for an Emergency Use Authorization (EUA) filing with the FDA in a matter of weeks. Read More
Merck’s blockbuster oncology drug Keytruda (pembrolizumab) significantly improved survival for women suffering from endometrial cancer when combined with Eisai’s Lenvima (lenvatinib) in a late-stage clinical trial, the companies announced Friday. Read More
In another blow to AstraZeneca’s (AZ) COVID-19 vaccine, a peer-reviewed study has found that it failed to protect against mild-to-moderate infections caused by the virus’ South African variant. Read More